Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.

被引：2

作者：

Vilbert, Maysa

Priantti, Jonathan N.

Madeira, Thiago

Moraes, Francisco Cezar A.

Tojjari, Alireza

Sahin, Ibrahim Halil

Cavalcante, Ludimila

Saeed, Anwaar

机构：

[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[2] Fed Univ Amazonas UFAM, Manaus, AM, Brazil

[3] Fed Univ Minas Gerais UFMG, Belo Horizonte, MG, Brazil

[4] Fed Univ Para UFPA, Belem, PA, Brazil

[5] Novant Hlth Canc Inst, Charlotte, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

261-566-9718-9794; 261-492-3532-2370-7650-2700; 283-424-6846-271-2644; 283-2494; 130-540-543-4790; 261-492-2769; 3282-3306-2666-6279; 7; 4; 3; 2; 1614; 1597; 8; 1; 38092-27449; 38092-20072; 6;

D O I：

10.1200/JCO.2024.42.3_suppl.366

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：366 / 366

页数：1

共 50 条

[41] Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma
Qiu, Rong
Wang, Wenxi
Li, Juan
Wang, Yuxiang
MOLECULAR BIOLOGY REPORTS, 2022, 49 (07) : 6633 - 6645
[42] First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers
Thierry Landre
Gaetan Des Guetz
Kader Chouahnia
Cherifa Taleb
Alain Vergnenègre
Christos Chouaïd
Journal of Cancer Research and Clinical Oncology, 2020, 146 : 441 - 448
[43] First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers
Landre, Thierry
Guetz, Gaetan Des
Chouahnia, Kader
Taleb, Cherifa
Vergnenegre, Alain
Chouaid, Christos
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (02) : 441 - 448
[44] PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy
Hong, Nicky Wong Zhun
Zhao, Joseph J.
Zhu, Ke Xin
Yap, Dominic Wei Ting
Kumarakulasinghe, Nesaretnam Barr
Huang, Yiqing
Sundar, Raghav
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[45] PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
Okadome, Kazuo
Baba, Yoshifumi
Yasuda-Yoshihara, Noriko
Nomoto, Daichi
Yagi, Taisuke
Toihata, Tasuku
Ogawa, Katsuhiro
Sawayama, Hiroshi
Ishimoto, Takatsugu
Iwatsuki, Masaaki
Iwagami, Shiro
Miyamoto, Yuji
Yoshida, Naoya
Watanabe, Masayuki
Komohara, Yoshihiro
Baba, Hideo
CANCER SCIENCE, 2022, 113 (02) : 399 - 410
[46] Variations in PD1, PD-L1, IDO1 and VEGR2 genes and association with outcomes in advanced head and neck squamous cell carcinoma (HNSCC) patients treated with anti-PD1/PD-L1 based immunotherapy
Saada-Bouzid, E.
Refae, S.
Ebran, N.
Gal, J.
Peyrade, F.
Guigay, J.
Milano, G.
ANNALS OF ONCOLOGY, 2017, 28
[47] Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trials
Liu, Zhefeng
Wang, Zhikuan
Zhu, Jun
Tao, Haitao
Huang, Ziwei
Han, Lu
Patel, Akshay J.
Hu, Yi
TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02)
[48] EFFICACY OF PD1/PD-L1 INHIBITORS VS CHEMOTHERAPY AS FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER AMONG PATIENTS WITH DIFFERENT PD-L1 EXPRESSION LEVELS
Lin, G.
Lingohr-Smith, M.
Deitelzweig, C.
Lin, J.
VALUE IN HEALTH, 2022, 25 (07) : S318 - S318
[49] PD-L1 in oral squamous cell carcinoma
Ragos, Vasileios
Mastronikolis, Nicholas S.
Tsiambas, Evangelos
Fotiades, Panagiotis P.
JOURNAL OF BUON, 2018, 23 (03): : 835 - 836
[50] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
Isla, Dolores
Sanchez, Alfredo
Casal, Joaquin
Cobo, Manuel
Majem, Margarita
Reguart, Noemi
Zugazagoitia, Jon
Bernabe, Reyes
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)

← 1 2 3 4 5 →